Clinical Trials Arena on MSN
EG 427’s HSV gene therapy reduces urinary incontinence in Phase Ib/IIa trial
French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback